With a personalized medicine approach, phenotypes must be characterized to adapt to the management of patients suffering from Hymenoptera venom anaphylaxis (HVA), including venom immunotherapy (VIT). In this systematic review, all articles mentioned systemic reactions with heterogeneous severity degrees. Half of those reported grade III-IV systemic reactions (Ring and Messmer). HVA clinical patterns could be worsened by one Hymenoptera sting, a patient's history with mast cell disorders, or cardiovascular diseases. VIT failure was attributed to bee venom extract and monotherapy in two-thirds of publications. Findings stress the difficulty of having uniform epidemiological data on HVA and the lack of financial support in some world regions to support appropriate management of these conditions. Although observing a heterogeneity of data, we were able to identify potential risk factors, in particular for the severe cases. We believe our work will support allergists and health professionals to implement improved personalized management of patients suffering from severe HVA.
Keyphrases
- systematic review
- electronic health record
- risk factors
- big data
- cardiovascular disease
- early onset
- oxidative stress
- healthcare
- single cell
- drug induced
- clinical trial
- case report
- data analysis
- type diabetes
- machine learning
- young adults
- risk assessment
- combination therapy
- coronary artery disease
- artificial intelligence
- cardiovascular events
- health insurance